Archive

Appointment of an Executive Director

Physiomics (AIM: PYC), the Oxford, UK, based systems biology company, is pleased to announce the appointment of Dr Mark Chadwick as Chief Executive…

Carbon Trust Grant

Physiomics (AIM: PYC), the Oxford, UK based systems biology company,is pleased to announce that the Company together with Green Biologics Limited (GBL) and North Energy…

Joint services alliance with Jubilant Biosys

Physiomics (AIM: PYC), the Oxford, UK based systems biology company, is pleased to announce that it has executed non legally binding head of terms…

Validation results

Physiomics have validated their Virtual Tumour model in single-blind experiments with a major pharma company. The model successfully predicted the outcome of two drug combination xenograft studies. The results are presented in an article for Innovations in Pharmaceutical Technology (June issue).

Biotech Info, 24 March 2010

Physiomics “fabrique“ des tumeurs virtuelles. (In French) "De la biologie cellulaire aux mathématiques appliqués, Physiomics construit ses modèles pour répondre à des problématiques biologiques. Essentiellement descriptifs à l’origine, ceux-ci deviennent de plus en plus prédictifs". (From cell biology to applied mathematics, Physiomics builds models to answer biological questions. Although such models were initially illustrative, they have become more and more predictive.) Features an interview of Dr Christophe Chassagnole, Physiomics COO, by Nathaly Mermet.

Collaboration with Sareum, the ICR and CRT

Physiomics (AIM: PYC), the Oxford, UK based systems biology company, and Sareum Holdings plc (AIM: SAR) are pleased to announce that they have signed an agreement in which Physiomics provides in silico simulations to support Sareum’s cancer drug joint research program with The Institute of Cancer Research (ICR) and Cancer Research Technology Limited (CRT).